Letter AI | $40,000,000 | (Feb 25, 2026)
Subject | $28,000,000 | (Feb 25, 2026)
Certified by Founder
Lodge
Slate Medicines
start up
United States
- Raleigh, NC
- 25/02/2026
- Series A
- $130,000,000
Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders. The company is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and an additional undisclosed biotech investor. For more information, please visit www.slatemedicines.com.
- Industry Biotechnology Research
- Website https://www.slatemedicines.com/
- LinkedIn https://www.linkedin.com/company/slate-medicines/
Brilliant Harvest Inc. | $4,000,000 | (Feb 25, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Slang AI | $36,000,000 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)
General Magic | $7,200,000 | (Feb 25, 2026)
Circadian Risk Inc. | $6,000,000 | (Feb 25, 2026)
Neural Earth | $9,300,000 | (Feb 25, 2026)
Jampack AI | $3,200,000 | (Feb 25, 2026)